Stay in the loop

Non-invasive cell-free DNA liquid biopsy platform for multi-organ monitoring of drug-safety across preclinical and clinical settings

Early access programme now open for drug developers to shape future platform capabilities and applications

New brand identity and website mark the expansion of Tagomics’ product portfolio into organ health monitoring

Tagomics’ Organ Health Programme Lead Dr John Gallon, Scientific Advisory Board member Professor Yuval Dor, and our partners at AstraZeneca have co-authored a paper recently published in JCO Precision Oncology exploring the next frontier in cfDNA applications: precision drug safety monitoring.

Enzymatic enrichment of unmethylated cell-free DNA improves the sensitivity of fragmentomic analysis for the diagnosis of patients with lung cancer.

- Study published in ‘Cell Reports Methods’ demonstrates the strength of Tagomics’ platform for epigenomic biomarker discovery and applications in liquid biopsy

- Activace platform enables targeted, genome-wide profiling of unmethylated DNA regions, providing a comprehensive view of the epigenome that can be scaled to the study of large patient cohorts

Robert Neely from Tagomics shares how simultaneous genomic and epigenomic profiling can drive more precise and timely healthcare.

Methylation profiling of cell-free DNA is opening new possibilities for detecting cancer at its earliest, pre-symptomatic stages, offering a potential breakthrough in how and when disease is found.